reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SCHL SCHOLASTIC CORPORATION
MRCY MERCURY SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
KURA KURA ONCOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HELE HELEN OF TROY LIMITED
CROX CROCS INC.
AIR AAR CORP.
UNFI UNITED NATURAL FOODS INC.
LINK INTERLINK ELECTRONICS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
IMTX IMMATICS N V (A)
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
COGT COGENT BIOSCIENCES INC
RLAY RELAY THERAPEUTICS
HIMS HIMS AND HERS HEALTH INC (A)
VERA VERA THERAPEUTICS INC
TNGX TANGO THERAPEUTICS INC
DSGN DESIGN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
MBC_w MASTERBRAND INC
IRON DISC MEDICINE INC
CTNM CONTINEUM THERAPEUTICS INC
PACS PACS GROUP INC
ZBIO ZENAS BIOPHARMA INC.
UPB UPSTREAM BIO INC
MIR MIRION TECHNOLOGIES INC
SION SIONNA THERAPEUTICS INC
KLRS KALARIS THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
EMPG EMPRO GROUP INC
Oxbridge / SurancePlus to Attend TOKEN2049 Singapore
Oxbridge / SurancePlus to Attend TOKEN2049 Singapore GRAND CAYMAN, Cayman Islands, Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced it will participate in Singapore, taking place October 1–2, 2025 at the Marina Bay Sands. TOKEN2049 Singapore brings together industry leaders, innovators, and decision-makers from across the globe to connect, exchange ideas, and shape the future of digital assets and Web3. The event draws participants from more ...
Oxbridge / SurancePlus: 2025/26 Tokenized Reinsurance on Track for Tar...
Oxbridge / SurancePlus: 2025/26 Tokenized Reinsurance on Track for Targeted Returns GRAND CAYMAN, Cayman Islands, Sept. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported that its ZetaCat Re and EtaCat Re tokenized reinsurance securities for the 2025/2026 treaty year are on track to achieve their targeted returns of 20% and 42%, respectively. On June 1, 2025, launched its tokenized reinsurance securities offerings for the 2025/2026 treaty year, which ...
Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics Appoints Justin Gover to Board of Directors CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
Soleno Therapeutics to Participate in Upcoming September Conferences
Soleno Therapeutics to Participate in Upcoming September Conferences REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Wells Fargo Healthcare ConferencePresentation Date: Thursday, September 4, 2025 at 1:30 ...
Design Therapeutics to Participate in the 2025 Cantor Global Healthcar...
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be...
Oxbridge Highlights Growth in Tokenized Reinsurance, Strategic Partner...
Oxbridge Highlights Growth in Tokenized Reinsurance, Strategic Partnerships, and Reports Q2 2025 Results GRAND CAYMAN, Cayman Islands, Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its results for the quarter and six-month period ended June 30, 2025. “The quarter marked a pivotal moment for and . We have not only expanded our footprint in the rapidly growing tokenized reinsurance market but also forged strategic partnerships that position u...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs ...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker Study for DT-168 Initiated in Patients with Fuchs Endothelial Corneal Dystrophy (FECD) Cash and Securities of $216.3 Million Support Continued Pipeline Advancement CARLSBA...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2...
Oxbridge Re Announces 2025 Second Quarter Results on Aug 14, 2025
Oxbridge Re Announces 2025 Second Quarter Results on Aug 14, 2025 GRAND CAYMAN, Cayman Islands, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Thursday August 14, 2025 at 4:30 p.m. Eastern time to discuss results for the second quarter ending June 30, 2025. Financial results will be issued in ...
Oxbridge / SurancePlus to Attend Rare Evo 2025 in Las Vegas
Oxbridge / SurancePlus to Attend Rare Evo 2025 in Las Vegas GRAND CAYMAN, Cayman Islands, July 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced its participation in Rare Evo 2025, a premier blockchain convention held August 6–10, 2025 at Caesars Palace in Las Vegas, Nevada. Rare Evo brings together blockchain projects, industry leaders, investors, and developers in a celebration of decentralized innovation and interoperability. With hundreds of exhi...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an ad...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject ...
Soleno Therapeutics Announces Preliminary Financial and Operational Re...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million....
Soleno Therapeutics Inc: 1 director
A director at Soleno Therapeutics Inc sold 3,830 shares at 82.760USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR...
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets, previously known as DCCR, have been selected for presentation at the Annual Meeting of the Endocrine Society (ENDO 2025), which is being held July 12-15, 2025, in San Francisco...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVAV AEROVIRONMENT INC.
KFS KINGSWAY FINANCIAL SERVICES
PAYS PAYSIGN INC
PRCH PORCH GROUP INC (A)
SPNT SIRIUSPOINT LTD
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
OSCR OSCAR HEALTH
JOBY JOBY AVIATION INC
COIN COINBASE GLOBAL INC
EVEX EVE HOLDING INC
GCT GIGACLOUD TECHNOLOGY INC
CRBG COREBRIDGE FINANCIAL INC.
SGHC SUPER GROUP (SGHC) LIMITED
RDW REDWIRE CORP
DAVE DAVE INC
GRALV GRAIL INC.
SMCI SUPER MICRO COMPUTER INC.
EVTL VERTICAL AEROSPACE LTD.
ANET ARISTA NETWORKS INC
OWLT OWLET INC
ESP BROMPTON ENERGY SPLIT CORP
Oxbridge / SurancePlus CEO Jay Madhu to Speak during Ethereum Communit...
Oxbridge / SurancePlus CEO Jay Madhu to Speak during Ethereum Community Conference (EthCC) – Cannes, at the Gamma Prime Investor Forum GRAND CAYMAN, Cayman Islands, June 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced its participation during the , to be held in Cannes, France, June 30–July 3, 2025. The event brings together blockchain builders, institutional investors, and capital allocators from around the world to explore the next wave of decentr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.